CBS 2019
CBSMD教育中心
English

Stenting Left Main

科研文章

荐读文献

Outcomes Among Patients Undergoing Distal Left Main Percutaneous Coronary Intervention Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial Successful bailout stenting strategy against lethal coronary dissection involving left main bifurcation Left Main Revascularization With PCI or CABG in Patients With Chronic Kidney Disease: EXCEL Trial Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease Contemporary Approach to Coronary Bifurcation Lesion Treatment Second vs. First generation drug eluting stents in multiple vessel disease and left main stenosis: Two-year follow-up of the observational, prospective, controlled, and multicenter ERACI IV registry Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial Radial versus femoral artery access in patients undergoing PCI for left main coronary artery disease: analysis from the EXCEL trial Coronary artery bypass graft surgery versus percutaneous coronary intervention in patients with three-vessel disease and left main coronary disease: 5-year follow-up of the randomised, clinical SYNTAX trial
|<< 1 2 3 4 5 6 7 ...>>|

Review Article2016 Dec;9(12).

JOURNAL：Circ Cardiovasc Interv. Article Link

Percutaneous Coronary Intervention Using Drug-Eluting Stents Versus Coronary Artery Bypass Grafting for Unprotected Left Main Coronary Artery Stenosis: A Meta-Analysis of Randomized Trials

Nerlekar N, Ha FJ, Brown AJ et al. Keywords: coronary angiography; coronary artery bypass; drug-eluting stent; meta-analysis; percutaneous coronary intervention

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top